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Background: Human telomerase reverse transcriptase (hTERT), the catalytic subunit of telomesase, is responsible for
telomere maintenance and its reactivation is implicated in almost 90% human cancers. Recent evidences show that
hTERT is essential for neoplastic transformation independent of its canonical function. However, the roles of hTERT
in the process remain elusive. In the current work, we explore the extra-telomeric role of hTERT in the neoplastic
transformation of fibroblast IMR90.
Results: Here we established transformed IMR90 cells by co-expression of three oncogenic factors, namely, H-Ras,
SV40 Large-T antigen and hTERT (RSH). The RSH-transformed cells acquired hallmarks of cancer, such as they can
grow under anchorage independent conditions; self-sufficient in growth signals; attenuated response to apoptosis;
and possessed recurrent chromosomal abnormalities. Furthermore, the RSH-transformed cells showed enhanced
migration capability which was also observed in IMR90 cells expressing hTERT alone, indicating that hTERT plays a
role in cell migration, and thus possibly contribute to their metastatic potential during tumor transformation.
This notion was further supported by our microarray analysis. In addition, we found that Ku70 were exclusively
upregulated in both RSH-transformed IMR90 cells and hTERT-overexpressing IMR90 cells, suggesting the potential
role of hTERT in DNA damage response (DDR).
Conclusions: Collectively, our study revealed the extra-telomeric effects of hTERT in cell migration and DDR during
neoplastic transformation.
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Human telomeres are TTAGGG repeats at the ends of
human chromosomes, protecting them from end-to-end
fusion and maintaining chromosomal stability [1,2]. In
human somatic cells, telomere length shortens in each
cell division as DNA polymerase is unable to replicate
the very end of telomere [3,4]. Eventually cells stop* Correspondence: bchwxy@nus.edu.sg
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unless otherwise stated.proliferating and undergo senescence. However, almost
90% of human cancers overcome the finite divisional po-
tential by reactivation of a ribonucleoprotein complex,
known as telomerase [5-7]. The catalytic subunit of
telomerase, telomerase reverse transcriptase (hTERT),
is the rate-limiting factor of telomerase activity. Up-
regulation of hTERT confers cells limitless proliferative
potential, which is one of the cancer hallmarks [8].
Emerging evidence suggests that maintenance of telo-
mere length might not the sole function of hTERT during
oncogenesis. For instance, knockdown of hTERT resulted
in rapid inhibition of cell proliferation and growth in
cancer cells without affecting the telomere length [9].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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meres attributed to increase risk of cancer formation [10],
which further support the notion that hTERT has other
functions, on top of its canonical function in telomere
maintenance. In addition, human cells utilize alternative
lengthening of telomeres pathway for telomere mainten-
ance can only be transformed when co-expressing hTERT
and oncogenic-Ras, indicating that hTERT is indispens-
able for cancer transformation [11,12]. Taken together,
these findings suggest that hTERT plays a key role in
tumorigenesis independent of its canonical function. Its
roles in neoplastic transformation, however, are still
not well understood. Therefore, investigating the roles
of hTERT in the cancer transformation is of utmost
imperative.
Neoplastic transformation can be achieved by in vitro
genetic manipulation. Studies showed that disruption of
the intracellular pathways regulated by SV40 Large-T,
oncogenic Ras and hTERT are sufficient to create a hu-
man tumor cell [13]. This highlighted the various path-
ways that require changes for transformation to occur:
the mitogenic response pathway activated by Ras [14];
telomere maintenance pathway by hTERT [4]; cell sur-
veillance pathways due to the functional abolishment of
p53 and Rb tumor-suppressors by Large-T [15]. Since
disruption of these cellular pathways are commonly seen
in in vivo tumors, tumor cells generated from such tran-
sformed cell model can be a good representation of ac-
tual human cancers [16]. This model also serves as a
platform to study the early stages of the tumor for-
mation, as compared to tumor biopsies that are often
obtained at an advanced stage [13].
Here, we transformed IMR90, a non-epithelial somatic
lung fibroblast, by three factors, including H-Ras, SV40
Large-T, and hTERT (RSH). Using the RSH-transformed
IMR90 cell model, our results unveiled the extra-
telomeric functions of hTERT in cell migration as well
as in DNA damage response during neoplastic trans-
formation. Therefore, our findings suggest that hTERT is
an attractive target for cancer therapy, even at early
stage of cancer formation.
Results and discussion
RSH-transformed cells acquire cancer cells characteristics
Primary human fibroblast cells IMR90 were successfully
co-transfected with Ras, SV40 Large-T, and hTERT and
their protein expressions were confirmed by western blot-
ting (Figure 1A). Morphologically, IMR90 RSH fibroblasts
appeared to be shorter and rounder compared to the infec-
tion control (Figure 1B). This observation is consistent with
the findings of Mason and colleagues in IMR90 cells trans-
formed with E1a/Ras [17], suggesting that these changes
are the unique characteristics of cellular transformation.
Moreover, late passages of IMR90 control cells underwentsignificant increase in cell sizes, indicating their senescent
status. However, this was not observed in IMR90 RSH cells
even after several passages (data not shown).
One of the hallmarks of the cancerous cells is they can
survive and grow in the absence of anchorage to the extra-
cellular matrix [18]. Our anchorage independent growth
assays demonstrated that IMR90 RSH cells formed small
microscopic colonies (<200 μm in diameter) while MCF-7
cells, the positive control, formed large visible colonies
(>200 μm in diameter) (Figure 1C) after 6 weeks. Com-
parison of colony sizes with MCF-7 suggests that trans-
formation by three genetic factors produced cells that
were less tumorigenic than the established cancer cells.
Thus, the RSH-transformed cell could serve as a represen-
tative model to study the early events of cancer transfor-
mation, compared to an established cell line.
Another common trait of cancer cells is their self-
sufficiency in growth signals [18]. To investigate the effects
of growth factors withdrawal on the RSH-transformed
cells, the cells were subjected to a serum-free environ-
ment, following which cell proliferation and survival were
assessed over a three-day period. As expected, IMR90
control cells showed signs of apoptosis after 24 hours of
serum withdrawal. However, no apoptosis was observed in
IMR90 RSH cells even after treating for 72 hours in
serum-free condition, suggesting that these RSH-trans-
formed cells were able to survive in the absence of growth
factors (Figure 1D). We further tested whether trans-
formed fibroblasts are refractory to the induction of apop-
tosis, which is commonly observed in cancer cells [19].
After treating with Doxorubicin (Dox), a DNA damage-
inducing drug for 48 hours, IMR90 RSH cells were able to
survive even at much higher Dox concentrations (3 μM
and 5 μM) than IMR90 control cells, reflecting an attenu-
ation in the apoptotic machinery of the cells (Figure 1E).
For potential use of IMR90 RSH as a cancer cell model,
we also assessed their chromosomal aberrations for re-
current abnormalities through cytogenetics study [20].
Karyotyping of IMR90 RSH cells revealed recurrent abnor-
malities (Figure 1F,G). Moreover, spectral karyotyping
analysis revealed that 60.9% (14 out of 23) of IMR90 RSH
cells had recurrent chromosomal abnormalities at chro-
mosomes 4, 18, 20 (Figure 1H; Additional file 1: Table S1).
Taken together, these data indicated that IMR90 cells were
successfully transformed by co-expressing three oncogenic
factors. The RSH-transformed fibroblasts acquired various
characteristics of a human cancer cell and may serve as a
valuable model to study the early events of tumorigenesis.
RSH-transformed cells and hTERT-overexpressing cells
demonstrate increased migration capability
Metastasis is often correlated to two attributes: migration
followed by invasion [21]. Metastatic tumors are believed
to occur in the late stages of cancer [22]. However, in
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Figure 1 Transformed IMR90 cells show characteristics of a cancer cell. (A) Western blot confirming the expression of the three genetic
factors Ras, hTERT and SV 40 Large T in the transformed IMR90 primary human cells. The expression of hTERT on the western blot was detected
using anti-FLAG antibody. (B) Changes in cellular morphology after RSH transformation. Transformation of IMR90 cells and resulted in shorter and
rounder cells. Left bottom corners show the enlarged pictures. (C) Soft agar assay determining the anchorage independence of the transformed
RSH cells in vitro. MCF-7 cells were used as the positive control. The experiment was carried out in triplicates. Representative image of one well is
shown. (D) Survival of IMR90 control and IMR90 RSH cells in serum-free medium. (E) Cells of IMR90 control and IMR90 RSH were treated with
1 μM, 3 μM and 5 μM of doxorubicin separately for up to 48 hours. (F) G-band Karyotype analysis of IMR90 control cells infected with control
vector and IMR90 RSH cells. Arrows indicate the presence of genetic aberrations. (G) Metaphase spreads of IMR90 RSH cells. White arrows indicate
the presence of genetic aberrations. (H) A representative spectral karyotype of a metaphase from IMR90 RSH cells. Recurrent abnormality is defined
as at least 3 metaphase cells having the abnormality at the same region of chromosomal location. Chromosomal abnormality can be observed at
chromosomes 4, 18, 20.
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even after the removal of non-invasive, benign tumors, sug-
gesting the possibility of the cancer cells undergoing metas-
tasis at a much earlier stage [23]. We questioned if IMR90
RSH cells possess migration capability similar to that of a
cancer cell. Our Boyden assay results showed that IMR90
RSH cells had a greater migration capability as compared
to IMR90 control cells (Figure 2A). This result was further
validated with wound healing assay, in which the gap was
reduced to 40% for IMR90 RSH cells compared to 84% in
IMR90 control cells (p < 0.01) (Figure 2B,C). Moreover, we
observed that IMR90 RSH cells migrated faster and in amore individualistic pattern compared to IMR90 control
cells, implying some degree of autonomy (Figure 2B).
Given that transformation can increase the migration
capability of cells and that hTERT is one of the upregu-
lated factors in the transformed cells, it then raised the
question as to whether hTERT alone can contribute to this
phenomenon. In order to assess the possible role of tel-
omerase in cell migration, we also performed wound hea-
ling assay on IMR90 cells expressing hTERT alone. Similar
to IMR90 RSH cells, the hTERT-overexpressing IMR90
cells (Figure 2D) also migrated faster than IMR90 control
cells (Figure 2E). However, when compared to IMR90
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Figure 2 Migration capability analysis of IMR90 RSH and IMR90 hTERT cells. (A) Boyden assay comparing the migration capability of IMR90
control and IMR90 RSH cells after 10 hours. (B) Wound healing assay comparing the migration of IMR90 control and IMR90 RSH cells after 9 hours
of incubation. Images at 0 hour and at 9 hours, representative of triplicate experiments for IMR90 control and IMR90 RSH cells, are shown. White
arrows indicate individual cells that have migrated. (C) The ‘wound closure’ areas are visualized under an inverted microscope and bar graphs
show the distance travelled by IMR90 control and IMR90 RSH cells in the wound healing assay. Results are indicated as the mean ± standard
deviation (SD) (n = 2). *p < 0.05; **p < 0.01; ***p <0.001. (D) Western blot confirming the overexpression of hTERT in IMR90 primary human cells.
(E) Wound healing assay comparing the migration of IMR90 control and IMR90 hTERT cells after 32 hours of incubation. Images at 0 hour and at
32 hours, representative of triplicate experiments for IMR90 control and IMR90 hTERT cells, are shown. White arrows indicate individual cells that
have migrated. (F) Bar graphs showing the distance travelled by IMR90 control and IMR90 hTERT cells in the wound healing assay. Results are
indicated as the mean ± standard deviation (SD) (n = 2). *p <0.05; **p < 0.01; ***p <0.001.
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started to occur only after 10 hours and they seemed to
have a slower migration rate. As shown in Figure 2E and
F, IMR90 hTERT cells migrated about 50% distance, yet
the distance was only reduced by 10% for IMR90 control
cells (p < 0.01). Collectively, these suggest that hTERT
does play a role in cell migration, which in turn contri-
butes to the metastatic potential of cancer cells.Microarray analysis supports the notion that hTERT plays
a role in cell migration
To investigate the underlying molecular basis of hTERT-
induced migration in transformed cells, we analyzed the
genome-wide gene expression in IMR90 RSH cells and
IMR90 hTERT cells. There were a total of 62 and 150
migration-related genes that were found to be differen-
tially expressed (fold change ≥ 2; p < 0.05) in IMR90 RSH
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differentially expressed genes, 28 genes were found to
be overlapped in both IMR90 RSH and IMR90 hTERT
cells (Table 1), suggesting that these genes may attri-
bute to migration during neoplastic transformation
and specifically, they were under the regulation of
hTERT. Approximately 93% of the genes were found to
be up-regulated by hTERT. Remarkably, pro-inflammatory
factors such as Interleukin-6 (IL6) and IL8 were sig-
nificantly enhanced in both RSH-transformed cells and
hTERT-overexpressing cells. Previous published data
demonstrated that IL6 and IL8 are targets under
hTERT-mediated regulation of NF-κB pathway [24].
On top of their role in inflammation, they are also




IL6 Interleukin 6 Positive regu
APOE Apolipoprotein E Negative re
COX-2 Cyclooxygenase-2 Positive regu
LAMA5 Laminin, alpha 5 Positive regu
IL8 Interleukin 8 Positive reg
BTG1 B-cell translocation gene 1 Positive regu
SCG2 Secretogranin II Positive reg
ETV4 Ets variant 4 Positive regu
CKLF Chemokine-like factor Positive regu
COL18A1 Collagen, type XVIII, alpha 1 Positive regu
LAMA1 Laminin, alpha 1 Positive regu
LAMA4 Laminin, alpha 4 Positive regu
MYH10 Myosin, heavy chain 10, non-muscle Positive regu
BBS2 Bardet-Biedl syndrome 2 Positive regu
WASF2 WAS protein family, member 2 Positive regu
TWIST1 Twist homolog 1 (Drosophila) Positive regu
NR4A2 Nuclear receptor subfamily 4, A2 Positive regu
SMAD3 SMAD family member 3 Positive regu
PLAT Plasminogen activator, tissue Positive regu
SEMA3F Semaphorin 3 F Positive regu
NUP85 Nucleoporin 85 kDa Positive regu
PALM Paralemmin Positive regu
ROBO3 Roundabout, axon guidance receptor, homolog 3 Positive regu
NDE1 nudE nuclear distribution gene E homolog 1 Positive regu
CDKN1B Cyclin-dependent kinase inhibitor 1B Negative re
LYN v-yes-1 Yamaguchi sarcoma oncogene Positive reg
PRKDC Protein kinase, DNA-activated, catalytic polypeptide Positive regu
ACTG1 Actin, gamma 1 Positive reguinvasion [25], which is corroborated with our microarray
data. Taken together, it is reasonable to hypothesize that
hTERT could enhance the cell migration through NF-κB
pathway in early tumorigenesis.
On the other hand, Liu et al. in 2013 have shown that
hTERT promotes the epithelial-mesenchymal transition
(EMT) by upregulating snail family zinc finger 1 (Snail1)
and vimentin through Wnt/beta-catenin signaling path-
way in gastric cancer [26]. We did not observe signifi-
cant changes in Snail-1 and vimentin genes expressions
in our cell models and this could be attributed to diffe-
rent cell model used in both studies. However, we noticed
that two downstream genes of Wnt/beta-catenin path-
ways, namely Cyclooxygenase-2 (COX-2) and Twist1 were
significantly enhanced in both RSH-transformed cells andH and IMR90 hTERT cells
on cell migration Fold change
IMR90 RSH vs control IMR hTERT vs control
lation of cell migration 14.135 2.665
gulation of cell motion 7.82747 5.968
lation of cell migration 6.094 2.475
lation of cell migration 4.273 2.498
ulation of locomotion 3.755 2.588
lation of cell migration 3.34 3.392
ulation of locomotion 3.051 3.563
lation of cell migration 3.047 2.884
lation of cell migration 2.865 3.246
lation of cell migration 2.738 4.533
lation of cell migration 2.631 6.232
lation of cell migration 2.582 2.3
lation of cell migration 2.495 5.678
lation of cell migration 2.479 2.415
lation of cell migration 2.421 5.506
lation of cell migration 2.409 3.328
lation of cell migration 2.398 3.488
lation of cell migration 2.396 3.602
lation of cell migration 2.367 3.977
lation of cell migration 2.348 5.71
lation of cell migration 2.214 3.579
lation of cell migration 2.151 2.42
lation of cell migration 2.116 2.929
lation of cell migration 2.115 2.388
gulation of cell motion 2.068 2.316
ulation of cell motion 2.032 4.017
lation of cell migration 2.024 3.337
lation of cell migration -5.041 -3.107
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plicated in cancer cell migration [27,28], and this is in
consistent with our microarray data. Taken together, our
microarray data complements with our previous notion
that hTERT play an important role in cell mobility,
which in turn contributes to the metastatic potential of
cancer cells.
hTERT might be implicated in DNA damage response via
upregulating Ku70 during IMR90 transformation
To delineate the roles of hTERT in neoplastic transfor-
mation, we performed mass spectrometry analysis on the
protein levels of IMR90 RSH cells. Surprisingly, analysis
by mass spectrometry revealed that protein Ku70 was
exclusively found in IMR90 RSH cells, but not in IMR90
control cells (Figure 3A; Additional file 2: Table S2).
Moreover, both RT-PCR and immunoblotting results con-
firmed our observation where Ku70 expression was aug-
mented in IMR90 RSH as well as IMR90 hTERT cells, but
not in IMR90 control cells (Figure 3B,C). This could be
indicative of an activated DNA damage responses (DDR)
in both IMR90-RSH and IMR90-hTERT since Ku70 is a
DDR sensor and is implicated in the non homologous end
joining (NHEJ) pathway [29]. Ku70 forms a heterodimeric
complex with Ku80 [30]. However, the protein expression
of Ku80 remained unchanged (Figure 3C). Presence of
Ku70 in IMR90 RSH cells and IMR90 hTERT cells prom-
pted us to assess whether other DDR-associated proteins
could be regulated by hTERT as well. Our microarray data
revealed that several DDR-associated genes were upre-
gulated in both RSH-transformed IMR90 and hTERT-
overexpressing IMR90 cells (fold change ≥ 2; p < 0.05)
(Additional file 3: Table S3). Taken together, these resultsA B 
RSH - + 
Ku 70 
GAPDH 





Figure 3 Ku 70 expression in IMR90-RSH and IMR90 hTERT cells. (A) C
cells and control fibroblasts, showing an augmented ~70 kDa (indicated by
IMR90 control, IMR90 hTERT and IMR90 RSH cells. Ku70 expression showed
control cells. (C) Ku70 protein expression in IMR90 control, IMR90 hTERT an
IMR90 RSH and IMR90 hTERT cells compared to IMR90 control cells.suggest that hTERT may play an important role in DDR
pathways, via Ku70 and other DDR-associated proteins.
Conclusions
In conclusion, the neoplastic transformation of human
primary fibroblast cells using SV40 Large-T antigen,
H-Ras and hTERT can be used as an in vitro cell model
for cancer studies, especially for those fibroblasts origi-
nated tumors. Moreover, our findings suggest that hTERT
is implicated in cell migration as well as DDR during
neoplastic transformation. As these processes have great
implications in cancer progression, our study could pro-
vide insights on the roles of hTERT and its underlying
mechanisms in human cancer formation.
Methods
Cell lines
Human breast cancer cells MCF-7 (HTB-22) and normal
human fibroblasts, including IMR90 (CCL-186) and BJ
(CCL-186) were purchased from American Type Culture
Collection (ATCC). Cells were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with
10% fetal bovine serum (FBS) (Gibco, Invitrogen),
2 mM L-glutamine (Gibco, Invitrogen) and 100U/ml
penicillin and streptomycin (Gibco, Invitrogen).
Infection and selection of cells
Retroviral pBabe-puro Ras V12 (Addgene Plasmid 1768),
and retroviral pBabe-puro SV40 LT (Addgene Plasmid
13970) were purchased from Addgene. FLAG was tagged
to the N-terminus of hTERT and cloned into a lentiviral
vector with Ires hygromycin mammalian selection. Retro-



















oomassie blue staining of the protein expression in RSH transformed
the black arrow). (B) Semi-quantitative analysis of Ku70 by RT-PCR in
an increase in IMR90 RSH and IMR90 hTERT cells compared to IMR90
d IMR90 RSH cells. Ku70 protein expression showed an increase in
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viral pBabe-puro vector (Addgene Plasmid 1764) was used
as infection control. IMR90 was infected with virus super-
natant with 8 μg/ml of polybrene for 24 hours. To gener-
ate stable cell line that co-expresses Ras, SV40 Large T
and hTERT, cells infected with RSH combination were se-
lected using both puromycin and hygromycin (Invitrogen)
for 5 days. Cells infected with pBabe-puro-hTERT as well
as pBabe-puro control vector were selected using puro-
mycin (InvivoGen) for 5 days. Cells stably expressing the
desired genes were further passaged and maintained on
selection medium for an additional two to three weeks
prior to downstream experiments.Anchorage-independent growth assay
104 cells were seeded in 0.3% (w/v) agarose with DMEM
and 16.66% FBS onto each well of a 24-well plate with a
0.6% (w/v) agarose underlay. Wells were analyzed for
colony formation after 6 weeks. Scoring was done by
counting the colonies under the microscope.Serum-free cell survival assay
105 cells were seeded and the number of living cells was de-
termined by Countess automated cell counter (Invitrogen)
after treating them in serum-free DMEM for 24, 48 and
72 hours.Drug treatment
105 cells were treated with Doxorubicin (Calbiochem) at
1 μM, 3 μM and 5 μM concentrations. The number of
living cells was determined by cell counting 24 and
48 hours after drug treatment.Immunoblotting
Immunoblotting was performed as described previously
[31]. The following antibodies were used: H-Ras (Santa
Cruz), SV40 Large-T (Santa Cruz), FLAG-Tag (Sigma),
hTERT (Epitomics), Ku 70 (Cell Signaling), Ku 80 (Cell
Signaling), α-tubulin (Sigma) and β-actin (Abcam).Wound healing assay
6-well plates were first coated with 10 μg/ml of collagen
(Cohesion) for two hours, followed by blocking with
BSA for one hour. 5 × 105 cells were seeded into the
wells and allowed to grow until confluent. Following
which, the cell monolayer was scratched at the bottom
of the wells. Culture medium was then replaced with
serum-free DMEM to minimize cell proliferation. Wells
were observed under the microscope at different time-
points and the distance of gap was measured. The per-
centage of wound closure was calculated from distances
quantified in three independent experiments.Boyden assay
Migration assay was performed using cell culture inserts
(BD Biosciences) with 8 μm pore size. 105 cells were di-
luted in 300 μl of serum-free DMEM supplemented with
0.1% (w/v) BSA and added to the upper chamber of the
well. 500 μl of normal culture DMEM supplemented with
100 ng/ml of human epidermal growth factor (ProSpec)
was added to the lower chamber and incubated for
10 hours. Following which, medium was removed from
both upper and lower chambers and cells were removed
by swabbing from the upper chamber. Cells from the
lower side of the insert were then stained with 1% crystal
violet and observed under the microscope.
Illumina microarray
Total RNA was extracted using RNeasy Mini Kit (Qiagen).
500 ng total RNA was used for cRNA amplification using
Illumina TotalPrep RNA Amplification kit (Ambion),
following manufacturers’ instructions. 750 ng cRNA
was then hybridized onto the HumanRef-8 v2 Sentrix
BeadChip (Illumina). Subsequently, the fluorescence emis-
sion by Cy3 was quantitatively detected by the Illumina
BeadArray Reader software for downstream analysis of
data by Partek software. Statistical significance of indi-
vidual gene expression levels was analyzed by Analysis of
variance (ANOVA) and significant genes were identified
based on fold-changes. Threshold for significance was
set at fold-change > ± |2.0| when compared to control
cells. Absolute intensity differences between experimental
groups were set at p < 0.05. All data is MIAME compliant
and the raw data has been deposited in a MIAME com-
pliant database (accession number: GSE24097).
RT-PCR and DNA gel electrophoresis
cDNA was used in a total of 25 μL PCR reactions con-
taining PCR buffer, DNA Taq polymerase, 200 nm of
each primer and dNTP. PCR products were resolved
using gel electrophoresis.
Metaphase spreads
Metaphase spreads were prepared as described in Jeppesen’s
protocol [32], with slight modifications. Slides were ob-
served using the Olympus Fluoview 1000 confocal micros-
copy system.
G-band karyotyping and spectral karyotyping
Cells at about 80% confluence were treated with colcemide
for mitotic arrest and harvested by standard hypotonic
treatment and methanol: acetic acid (3:1) fixation. For
G-band karyotyping, slides were prepared by standard air
drying method and G-band karyotype was performed ac-
cording to the published protocols. For spectral karyo-
typing, slides were prepared by standard air drying method
and hybridized with Human SKY paint probe (ASI), as per
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analyzed by SKY analysis. Identified chromosomal abnor-
malities were described according to the International Sys-
tem for Human Cytogenetic Nomenclature (ISCN) (1995).
Recurrent abnormalities are defined as at least 3 meta-
phase cells having the abnormality at the same region of
chromosomal location or those that are involved in > 3%
of cases.
Coomassie blue staining and mass spectrometry
Coomassie blue staining was performed on 7% and 15%
SDS-PAGE gel. Bands were excised at 70 kDa and the spots
were rehydrated in digestion buffer containing sequencing
grade modified trypsin at 37°C. Digested peptides were ex-
tracted from gel with TFA extraction buffer and desalted
using C-18 Zip-tips (Millipore). Mass spectra of the pep-
tides in each sample were obtained by MALDI-TOF. Pro-
tein identification was based on peptide fingerprint mass
mapping and peptide fragmentation mapping.
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